chronic%20obstructive%20pulmonary%20disease
CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Chronic obstructive pulmonary disease (COPD) is an inflammatory respiratory disease characterized by reversible airflow limitation.

The patient usually has chronic cough, sputum production or dyspnea with or without history of risk factors for the disease.

The chronic airflow limitation is caused by a combination of small airways disease and parenchymal destruction.

It is a preventable and treatable disease.

Chronic Obstructive Pulmonary Disease Drug Information

Drug Information

Indication: Bronchial asthma. Respules: Acute laryngotracheobronchitis (croup) in infants & childn.

Indication: Regular treatment of COPD including chronic bronchitis & emphysema. Accuhaler: Regular treatment of asthma...

Indication: Maintenance bronchodilator treatment for symptomatic relief of COPD. Add-on maintenance bronchodilator treatme...

Indication: Regular treatment of asthma where use of combination (inhaled corticosteroid & long-acting β2

Indication: Once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients w/ COPD.

Indication: Bronchodilator for maintenance treatment of bronchospasm associated w/ COPD including chronic bronchitis &...

Indication: Bronchodilator for maintenance treatment of bronchospasm, associated w/ COPD, including chronic bronchitis, em...

Indication: Bronchodilator for the prevention & treatment of symptoms in chronic obstructive airway disorders w/ rever...

Indication: Bronchodilator for the prevention & treatment of symptoms in chronic obstructive airway disorders w/ rever...

Indication: Symptomatic treatment of acute asthma attacks; bronchial asthma & other conditions w/ reversible airway na...

1  /  14
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 05 Oct 2020
Regular, low-dose, oral sustained-release morphine improved the health status of patients with moderate-to-very-severe chronic breathlessness due to chronic obstructive pulmonary disease (COPD), the MORDYC* trial has shown, validating its palliative role for chronic breathlessness.